Hepatitis B Virus (HBV) Antigens & Antibodies

Research-grade reagents for Hepatitis B Virus (HBV) — a partially double-stranded DNA virus (family Hepadnaviridae) that causes acute and chronic hepatitis, with chronic infection being a leading driver of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. HBV encodes four overlapping open reading frames producing surface antigens (HBsAg: L/M/S envelope glycoproteins including the preS1/preS2 domains critical for NTCP receptor binding), core/precore proteins (HBcAg capsid and secreted HBeAg), the multifunctional transactivator protein X (HBx), and the viral polymerase. We offer recombinant antibodies, monoclonal antibodies, reference antibodies (research biosimilars), InVivoMAb functional-grade antibodies, polyclonal antibodies, and recombinant proteins targeting all four major viral antigens (HBsAg, HBcAg, HBeAg, HBx), validated for ELISA, Western blot, immunohistochemistry, neutralization, and functional blocking assays. Multi-genotype coverage supports HBsAg seroconversion monitoring, capsid assembly modulator screening, therapeutic antibody benchmarking, diagnostic assay development, and functional cure research. RUO

Recombinant Antibodies Sequence-defined clones targeting HBsAg/L glycoprotein (5a19, KR127, G10, SAA2756), the preS2 domain (F124), HBeAg (E6#), and HBcAg (E13#, E21#). Includes a pan-genotype HBsAg clone (KR127) and FITC-conjugated format for direct immunofluorescence detection. Suitable for epitope mapping, genotype-specific serological discrimination, and HBsAg quantification assay development.

Monoclonal Antibodies Multiple hybridoma-derived clones targeting HBsAg, HBeAg, and HBcAg — providing matched capture/detection antibody pairs optimized for sandwich ELISA development. Multi-clone panels enable antibody pair screening, epitope binning, and lot-to-lot bridging studies for diagnostic kit manufacturing and quality control.

Reference Antibodies (Research Biosimilars) Research-grade analogs of clinical-stage anti-HBsAg therapeutic antibodies, including Tuvirumab (OST577), Exbivirumab, Libivirumab, VIR-3434, Lenvervimab (GC-1102), Tobevibart, Libevitug, and Brelovitug. For mechanism-of-action studies, competitive binding assays, pharmacokinetic modeling, and as benchmarking standards in HBV functional cure antibody discovery programs.

InVivoMAb Functional-Grade Low-endotoxin, azide-free anti-HBsAg antibodies targeting S-HBsAg (SHB) and S/L-HBsAg (L glycoprotein) of HBV genotype A. Validated for in vivo viral neutralization, passive immunoprophylaxis, HBsAg clearance studies, and functional blocking in HBV-transgenic and humanized mouse models used in therapeutic vaccine and cure research.

Polyclonal Antibodies Broad epitope recognition reagents targeting HBsAg, HBcAg (capsid protein), HBeAg (precore/secreted antigen), and HBx (transactivator protein X). Validated for Western blot, ELISA, and immunohistochemistry. HBx-specific polyclonal antibody supports studies of HBV-driven hepatocarcinogenesis, cccDNA transcriptional regulation, and epigenetic reprogramming.

Recombinant Proteins His-tagged, SUMO-tagged, and S-tagged HBV antigens covering HBsAg (genotype B and adr subtype), HBcAg/capsid protein, HBeAg, and HBx. Validated for SDS-PAGE and Western blot. Suitable as coating antigens for serodiagnostic ELISA development, immunogens for antibody generation, capsid assembly screening substrates, and reference standards for vaccine potency and serological surveillance assays.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545-558. DOI

2. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972-1984. DOI

3. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012;1:e00049. DOI

4. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672-686. DOI